Daiwa Pharmaceutical Co., Ltd. (Setagaya-ku, Tokyo, Japan - President: Yasuo Ninomiya) has put BioBran 250, the new line of our main product BioBran (rice bran Arabinoxylan derivative), on the market. The product was released this April and placed in large-scale drug stores (BioBran 250 mg / tablet x 50 tablets, \6,825 [tax included]).

Our long-selling BioBran products have established the word "Arabinoxylan" in the market. We have added BioBran 250 (tablets) to the series; Lentin Plus 1000 (granules) and Lentin Plus γ(soft capsules), as there had been a strong demand for a tablet type product.

BioBran 250 contains 250 mg of BioBran in each tablet. Suggested dosage for health maintenance is 2 to 4 tablets daily. BioBran (rice bran Arabinoxylan derivative) has been developed and manufactured based on our unchanging philosophy of bringing out the beneficial functions of traditional Japanese foods through the application of advanced bioscience. We have patented the process in Japan and 9 other countries. A wealth of evidence comprising more than 20 articles and 50 academic presentations supports the outstanding sales performance in 30 countries.

BioBran 250 is the third leading product in our product series, now that we are looking forward attracting new customers.

・

Copyright(C)2006 Daiwa Pharmaceutical Co.,Ltd. All rights reserved. | HOME >